**MINUTES**

**CPIC CONFERENCE CALL**

DATE: October 3, 2019

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping Announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a doodle link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Kelly will send the poll link. |
| CPIC update | Kelly presented an overview of CPIC accomplishments over the past year (slides attached with minutes).  Guideline updates in progress:   * *CYP2C9/HLA/*phenytoin: Drafting recommendation * *CYP2D6*/opioid: Drafting recommendation; evidence review underway for OPRM1 and COMT * *CYP2C19/*clopidogrel: Evidence review underway   New guidelines in progress:   * *CYP2C19/*PPIs: Drafting guideline * *CYP2C9/*NSAIDs: Kelly will send this out for CPIC member review soon * *mtRNR1*/aminoglycosides: authorship plan underway; if you know of any experts on this topic, please email Kelly (Kelly.caudle@stjude.org) | Guideline preparation will continue and Kelly will continue to follow-up. |
| PGx insurance coverage decisions | Mary gave an overview of the proposed local coverage (LCD) for pharmacogenomics on the Medicare coverage database. It is posted now until November 21, 2019 for public review and comment. CPIC is planning to comment. If you would like to participate, email Kelly ([Kelly.caudle@sjtude.org](mailto:Kelly.caudle@sjtude.org)). Mary also mentioned the United Healthcare Pharmacogenetic testing coverage (see slides attached with minutes). | Mary will continue to update. |
| US PGx testing/FDA environment | Mary reviewed ongoing initiatives regarding the FDA and PGx testing including AMP’s position statement (<https://www.amp.org/AMP/assets/File/position-statements/2019/Best_Practices_for_PGx_9_4_2019.pdf?pass=98>), the American Clinical Laboratory Association’s (ACLA) letter to the FDA (<https://www.acla.com/wp-content/uploads/2019/09/ACLA-Letter-to-FDA-re_-PGx-Test-Policy-Sept-18-2019.pdf>), the Personalized Medicine Coalition, the possibility of pursuing to pursue a Collaborative Community with the FDA (<https://www.fda.gov/about-fda/cdrh-strategic-priorities-and-updates/collaborative-communities-addressing-healthcare-challenges-together>), the FDA’s new guidance document on Clinical Decision Support Software, and the STRIPE (standardizing laboratory practices for pharmacogenomics) initiative. She also discussed CPIC’s and PharmGKB’s discussions with the FDA regarding possible FDA recognition. | Mary will continue to update. Matt Rutledge volunteered to lead looking into an FDA collaborative community for Pgx. |
| PGRN poster session at ASHG | ​The PGRN Poster Session & Reception will be held on October 17th, 2019 during the 2019 ASHG Annual Meeting in Houston. To register, go to <https://www.pgrn.org/ashg-2019.html>. | n/a |